Glioblastoma stem-like cells (GSC) promote tumor initiation, progression and therapeutic resistance. Here we show how GSC can be targeted by the FDA approved drug mibefradil which inhibits the T-type calcium channel Cav3.2. This calcium channel was highly expressed in human GBM specimens and enriched in GSC. Analyses of the TCGA and REMBRANDT databases confirmed upregulation of Cav3.2 in a subset of tumors and showed that overexpression associated with worse prognosis. Mibefradil treatment or RNAi-mediated attenuation of Cav3.2 was sufficient to inhibit the growth, survival and stemness of GSC, and also sensitized them to temozolomide (TMZ) chemotherapy. Proteomic and transcriptomic analyses revealed that Cav3.2 inhibition altered cancer signaling pathways and gene transcription. Cav3.2 inhibition suppressed GSC growth in part by inhibiting pro-survival AKT/mTOR pathways and stimulating pro-apoptotic survivin and BAX pathways. Further, Cav3.2 inhibition decreased expression of oncogenes (PDGFA, PDGFB, and TGFB1) and increased expression of tumor suppressor genes (TNFRSF14 and HSD17B14). Oral administration of mibefradil inhibited growth of GSC-derived GBM murine xenografts, prolonged host survival and sensitized tumors to TMZ treatment. Our results offer a comprehensive characterization of Cav3.2 in GBM tumors and GSC, and provide a preclinical proof of concept for repurposing mibefradil as a mechanism-based treatment strategy for GBM.
INTRODUCTION
Glioblastoma (GBM) is the most common primary malignant brain tumor. GBM is associated with a dismal prognosis and an average life expectancy of ~15 months despite optimal therapy consisting of surgery, chemotherapy and radiation (1) . Lack of therapeutic success is attributed to various factors including rapid tumor cell infiltration of the brain, inter-and intra-tumoral heterogeneity, limited diffusion of therapeutic drugs across the blood brain barrier and brain/tumor parenchyma as well as to the presence within the tumor of GBM stem cells (GSCs) that are resistant to radio-and chemotherapy and that are capable of tumor generation and unlimited self-renewal (2) (3) (4) (5) . Overcoming GSC resistance to existing therapies or induction of GSC differentiation could greatly enhance therapeutic outcome.
Calcium signaling plays a ubiquitous role in many cellular regulatory processes (6-9) including proliferation, apoptosis and gene transcription (10) (11) . Additionally, alteration of free cytosolic calcium results in the transcription of immediate early genes (12) (13) such as c-fos, c-jun, the cyclic AMP response element and the serum response element. Expression of these genes triggers entry into the cell cycle through expression of cyclins and cyclin-dependent kinases (14) (15) (16) (17) . Calcium influx is mediated by voltage-gated Ca++ (Cav) channels (18) of which there are five types: L-type, P-type, N-type, R-type and T-type. Aberrant expression and activity of T-type calcium channels (Cav3.2) has been implicated in cancer (19) through their role in the regulation of cell cycle progression. In line with this, an increase in intracellular calcium, regulated by Cav3.2 expression, has been shown to regulate GBM cell proliferation (20, 21). 
MATERIALS AND METHODS

Cells and tumor specimens
Human GBM cell lines U87, A172, U373, T98G and SNB19, were obtained from American Type Culture Collection (Manassas, VA) within the last four years and used at less than 20 passages.
U1242, U251 and SF767 were kind gifts from Dr. Isa Hussaini and Dr. Benjamin Purow (University of Virginia), and Dr. Russel Pieper (UCSF), respectively. They were obtained within the last 10 years and used at less than 35 passages. Primary glioblastoma cells (GBM-6 and GMB-10), a gift from Dr. Jann Sarkaria (Mayo Clinic), were isolated from patients who underwent surgery at the Mayo clinic and were used at less than 10 passages (24). GSCs XO-1, XO-2, XO-3, XO-4, XO-8 and XO-9, kindly offered by Dr. Deric Park, were isolated from GBM specimens obtained from patients undergoing surgery at the University of Pittsburgh and were used at less than 8 passages. GSCs 206, 827 and 578 (used at less than 12 passages) were isolated from patient surgical specimens. GSCs were characterized for in vivo tumorigenesis, pluripotency, self-renewal, stem cell markers, and neurosphere formation (25). Matched CD133-positive and CD133-cells were isolated from GBM surgical specimens (used at one passage) were kindly provided by Dr. Rainer Glass (University Clinics Munich, Germany). All cell lines underwent testing for species and mycoplasma infection using Mycoplasma Detection KitQuickTest (Biotool, Houston, TX). GBM surgical specimens were obtained from the University of Virginia Brain Tumor Bank according to procedures that were approved by the Review Board of the University of Virginia. All tumors were characterized by an experienced neuropathologist.
Immunoblotting
Immunoblotting was performed as previously described (26). Antibodies used were Cav3.2, Nestin, Tuj-1 and HIF1α (Santa Cruz Biotechnologies, Santa Cruz, CA), p27, GFAP, BMI1, MAP2, Bax, Sox2, mTOR, HIF2 and PARP (Cell Signaling, Beverly, MA), β-actin and GAPDH (Santa Cruz Biotechnologies, Santa Cruz, CA).
Quantitative RT-PCR. Total RNA was extracted from GSCs using RNeasy extraction kit (Qiagen, Germantown, MD). cDNA was synthesized using the iScript cDNA synthesis kit (BioRad, Hercules, CA) and quantitative PCR analysis was performed using the CFX Connect Real-time System (BioRad Hercules, CA). GAPDH was used as an endogenous control. Primer sequences are listed in the Supplemental Methods.
Cell transfections. Lentiviral control vectors (sh-control) or vectors encoding Cav3.2 shRNA (sh-Cav3.2; pooled) (Santa Cruz Biotechnologies, Santa Cruz, CA) or two additional sh-Cav3.2 (Applied Biological Materials, Richmond, BC) were generated. GSCs were seeded in poly-Lornithine pre-coated plates and infected with the lentivuruses.
Cell death and cell proliferation assays. Cell death was assessed by trypan blue assay. Cell proliferation was assessed by cell counting for five days as previously described (27 
Reverse Phase Protein Arrays
Proteomic screening was performed by reverse phase protein array (RPPA) as previously described (28) (29) (30) . Protein analytes were chosen for analysis based on their previously described involvement in key aspects of tumor biology. All antibodies were validated for single band specificity and for ligand-induction (phospho-specific antibodies) by immunoblotting prior to use on the arrays as previously described (28) (29) (30) . Additional details are in the Supplementary Methods.
RNA sequencing
GSCs were treated with mibefradil (5 µM) or vehicle control for 24 h or transfected with shCav3. 2 
Rescue Experiments
Functional rescue experiments were performed to determine if molecules regulated by mibefradil from proteomic and transcriptomic screenings mediate the effects of mibefradil on GSCs. The experimental details are described in the Supplementary Methods.
In vivo experiments
The therapeutic effects of inhibiting Cav3.2 with mibefradil were assessed using an orthotopic GSC-based xenograft mouse model. GSC 827 cells (3 × 10 5 ) were stereotactically implanted into the corpus striatum of immunodeficient mice (n = 10 per treatment group). Six days after implantation, the animals were treated with control (H 2 O) or mibefradil (24 mg/kg) by oral gavage every 6 h and/or TMZ (100 mg/kg body weight) IP once a day for 4 days. Treatment stopped for 7 days. Mice were treated for two cycles. Tumor volumes were visualized and quantified by MRI and animal survival was determined.
Immunohistochemistry
Immunohistochemistry (IHC) was used to assess the expressions of Ki67, cleaved Caspase 3, SOX2 and GFAP in brain tumor xenograft sections. IHC was performed as previously described 
Statistical analyses
To evaluate the statistical significance of in vivo animal experiments, we used both two-sample t-test and non-parametric Wilcoxen rank-sum test. The continuous variable reverse phase protein array data generated were subjected to both unsupervised and supervised statistical analyses. Statistical analyses were performed on final microarray intensity values obtained using R version 2.9.2 software (The R Foundation for Statistical Computing). If the distribution of variables for the analyzed groups were normal, a two-sample t-test was performed. If the variances of two groups were equal, two-sample t-test with a pooled variance procedure was used to compare the means of intensity between two groups. Otherwise, two-sample t-test without a pooled variance procedure was adopted. For non-normally distributed variables, the Wilcoxon rank sum test was used. Significance levels were set at p < 0.05.
For RNA-seq, Raw FASTQ sequencing reads were chastity filtered to remove clusters having outlying intensity corresponding to bases other than the called base. Filtered reads were assessed for quality using FastQC. Reads were splice-aware aligned to the Ensembl GRCh38 genome using STAR (32) , and reads overlapping GRCh38.82 gene regions were counted using featureCounts (33) . The DESeq2 Bioconductor package (34) (Fig. 1D upper panel) . The REMBRANDT analysis also showed worse survival with high expression of Cav3.2 at thresholds of 25 percentile (Fig. 1D bottom panel).
The above data demonstrate that Cav3.2 is highly expressed in a subset of GBM tumors and GSCs and that high expression may correlate with poor prognosis. 
Cav3.2 blockade inhibits cell growth, induces cell death and enhances the effect of temozolomide (TMZ) in GSCs.
To assess the effects of Cav3.2 inhibition on GSC function, we first tested the effects of mibefradil on cell growth, proliferation and death, also in combination with TMZ. GSCs (827, 206, 578) were treated with mibefradil (2.5-5 µM) and / or with TMZ (400 nM) and analyzed for growth by Alamar blue assay. The results showed that mibefradil significantly inhibited cell growth and enhanced the inhibition of GSC growth by TMZ ( Fig. 2A) . To determine the effects of mibefradil on GSC proliferation, cells were treated with mibefradil (5 µM) and/or TMZ (400 nM) and counted for 5 days. Mibefradil significantly inhibited cell proliferation and enhanced the inhibition of GSC proliferation by TMZ (Fig. 2B ). To determine whether mibefradil affects cell death, we treated cells as above and performed a trypan blue assay. The results showed that mibefradil significantly enhances cell death also in combination with TMZ (Fig. 2C) . The above data show that mibefradil exhibits anti-cancer stem cell effects also in combination with TMZ.
Cav3.2 blockade induces glioblastoma stem cell differentiation
Cav3.2 has been associated with differentiation of mouse embryonic stem cells (35) . Based on that, we hypothesized that Cav3.2 might also regulate GSCs. To test this hypothesis, we determined the effects of mibefradil on the in situ expression of stemness and differentiation markers in GSCs using immunocytochemistry for the stemness and differentiation markers Sox2, GFAP and Tuj1. Mibefradil treatment increased the differentiation markers, GFAP (astrocytes) and Tuj1 (neurons) (Fig. 2D ) and inhibited expression of stem cell markers Sox2 (Fig. 2D) . We confirmed the downregulation of stemness markers Nestin, Bmi1 and Sox2 as well as the upregulation of differentiation markers GFAP and MAP2 through immunoblotting (Fig.   2E ). We also found, through RPPA, that mibefradil treatment decreased the protein level of CD133 whilst simultaneously increasing the level of GFAP (Fig. 4D) . The above data indicate that mibefradil induces GSC differentiation. 
Cav3.2 knock-down induces cell death and inhibits proliferation of GSCs
To confirm that the cell death and growth suppression induced by mibefradil was attributed to inhibition of Cav3.2, we silenced Cav3.2 with shRNA and analyzed the effect on cell proliferation and death. Cells were infected with lentivirus encoding either sh-control or sh-Cav3.2 for 48 h.
Cav3.2 knockdown by sh-Cav3.2 was verified by immunoblotiing (Fig. 3A) . The cells were counted at 3 and 5 days after lentivirus infection. Cav3.2 silencing significantly inhibited cell proliferation of GSCs (Fig. 3B) . To assess whether Cav3.2 silencing affected cell death, cells were infected as above and a trypan blue assay was performed. The data showed that silencing of Cav3.2 significantly enhanced cell death (Fig. 3C) . To exclude off target effects of sh-Cav3.2, we used two additional sh-Cav3.2 and found similar effects on cell proliferation and death ( Supplementary Fig. 3 ). The above data show that silencing of Cav3.2 expression leads to comparable anti-cancer effects on GSCs as mibefradil treatment.
Mibefradil inhibits hypoxia inducible factors HIF1α and HIF2 in GSCs
Hypoxia and HIF levels have been associated with GSC maintenance and resistance to therapy (36) (37). We hypothesized that Cav3.2 inhibition might affect hypoxia-induced HIF1 and HIF2 in GSCs. Thus we determined Cav3.2 expression in a hypoxic environment and the effect of mibefradil on HIF1α and HIF2 expression. GSCs were grown in 1% oxygen for 24 h and the level of Cav3.2 was determined by immunoblotting. Hypoxia induced Cav3.2 expression (Supplementary Fig. 2A ). HIF1α and HIF2 were increased in GSCs under hypoxic conditions compared to normoxic conditions ( Supplementary Fig. 2B, 2C ). HIF1α and HIF2 expressions were significantly suppressed by mibefradil treatment (Supplementary Fig. 2B, 2C ), suggesting that mibefradil might overcome GBM resistance to chemotherapy partially through inhibition of HIF1α and HIF2 in GSCs. 
Cav3.2 blockade inhibits several major oncogenic pathways in GSC.
To investigate the mechanism of action of Cav3.2 blockade with mibefradil in GSCs, we performed proteomic screenings using Reverse Phase Protein Arrays (RPPA) in GSCs treated with or without mibefradil for 1 or 24 h. The arrays measured the expressions and activation of > 300 proteins associated with cancer. mibefradil induced dramatic and significant changes in GSC signaling including inhibition of the AKT/mTOR pro-survival pathway as evidenced by decreased activation of AKT, mTOR and 4EBP1 and upregulation of LKB1 and Tuberin/TSC2 phosphorylation (Fig. 4A) . Mibefradil also induced signaling changes associated with the induction of cell cycle arrest and apoptosis including inhibition of survivin and activation of BAX, Caspase 9, PARP, p27 and Rb (Fig. 4B, 4C ). Mibefradil also affected molecules associated with DNA damage repair and autophagy (activation of ATM and LC3B) (Fig. 4C) . Additionally, mibefradil inhibited the expression of the stemness marker CD133 and increased the expression of the astrocytic marker GFAP (Fig. 4D) . Select random RPPA results (changes in p27, BAX, and cleaved PARP) were verified by immunoblotting (Fig. 4E) . The above data show that mibefradil-mediated Cav3.2 inhibition inhibits GSC malignancy by acting on multiple key cancer regulatory pathways.
Cav3.2 blockade induces apoptosis and inhibits cell proliferation via Bax, p27 and mTOR.
To determine if BAX and p27 mediate the pro-apoptotic effect of mibefradil, we assessed the effects of silencing p27 and BAX on mibefradil-induced cell death. We transfected GSC cells with either si-control, si-BAX or si-p27 before treating them with mibefradil for 48 h. Inhibition of either BAX or p27 abrogated mibefradil-induced cell death (Fig. 5A) . Silencing of BAX and p27 was confirmed by immunoblotting (Fig. 5B) . In order to deduce the role of mTOR in mibefradilmediated suppression of proliferation and cell death, we overexpressed mTOR prior to treating GSCs with mibefradil for 48 h. Overexpression of mTOR partially mitigated mibefradil-induced cell death and growth suppression (Fig. 5C) (Fig. 5D) . The above data show that the anti-cancer effects of Cav3.2 inhibition are partly mediated by the induction of apoptosis and inhibition of cell cycle progression via regulation of mTOR, BAX and p27.
Cav3.2 blockade alters gene expression in GSCs.
Since calcium is required for gene transcription (38) (39), we hypothesized that mibefradil might alter gene expression in GSCs. To test this hypothesis, we performed RNA deep sequencing (RNA-seq) on GSCs treated with vehicle control or mibefradil for 24 h. Mibefradil significantly altered the expression of many genes (Fig. 6A, 6B) . The RNA-seq data were partially verified by qRT-PCR (Fig. 6C) . Notably, mibefradil induced the expression of several tumors suppressors such as TNFRSF14 and HSD17B14 whilst simultaneously downregulating the expression of several oncogenes such as PDGFA, PDGFB, TGFB1, METTL7B, EGR3 and TNFRSF12A in GSCs. Interestingly, mibefradil-induced inhibition of METTL7B, a novel oncogene found overexpressed in primary stem-like GBM (40) , and EGR3 (41) both of which may partially account for mibefradil-induced differentiation as well as decreased GSC proliferation and survival. RNA-seq data were deposited at the GEO Database (Accession # GSE95106).
Cav3.2 blockcade inhibits in vivo tumor growth and enhances the effects of temozolomide.
We tested the effects of mibefradil alone and in combination with TMZ on the growth of established GSC xenografts and animal survival. GSC 827 cells (3 x 10 5 ) were stereotactically implanted in the striata of immunodeficient mice (n = 10). Six days after implantation, mibefradil (24 mg/kg body weight) was administered per oral gavage every 6 h for 4 days. TMZ (100 mg/kg body weight) was concurrently administered IP once a day for 4 days. The above treatment plan was repeated 7 days later. MRI scans were performed 21 days after surgery and tumor sizes were measured. Animal survival was also assessed. The data show that mibefradil Combined treatment with mibefradil and TMZ inhibited tumor growth in an additive fashion (Fig.   7A, 7B) . Similarly, both mibefradil and TMZ alone significantly prolonged animal survival with the combination of both drugs further prolonging animal survival (Fig. 7C) .
Immunohistochemical analysis of the xenografts revealed downregulation of the proliferation marker Ki67 and upregulation of the apoptosis regulator cleaved caspase 3 in mibefradil-treated xenografts. The expression of stem cell marker SOX2 was decreased, while the astrocyte marker GFAP was elevated in mibefradil-treated tumors (Fig. 7D) . These data suggest that mibefradil is a promising drug for GBM therapy. To establish whether the anticancer properties of mibefradil are attributed to inhibition of Cav3.2, we used shRNA to specifically silence Cav3.2. Silencing of Cav3.2 displayed similar anticancer effects as mibefradil treatment. This indicates that inhibition of Cav3.2 is the primary mechanism through which mibefradil exerts its known anticancer effects. We also discovered that Cav3.2 is upregulated in GSCs under hypoxic conditions and, importantly, mibefradil downregulated HIF1α and HIF2. Hypoxia strongly correlates with poor patient survival, therapeutic resistance and an aggressive tumor phenotype.
DISCUSSION
Changes in intracellular Ca
It was also previously demonstrated that GSCs are critically dependent on the HIFs for survival, self-renewal, and growth (47, 48) . This suggests that mibefradil can inhibit GSC malignant parameters by reducing hypoxic pressure and inhibiting HIFs.
We investigated the mechanism of action of mibefradil on GSC. Using proteomic screening, immunoblot validation and functional rescue experiments, we found that cell cycle and apoptosis signaling pathways are significantly activated by mibefradil in GSCs, including decreased phosphorylation of AKT, mTOR and 4EBP1 and upregulation of p27 KIP1, BAX, FOXO1 and cleaved PARP leading to decreased tumor cell proliferation through downregulation of key survival pathways and cell cycle arrest, respectively. Furthermore, silencing of p27 or Bax, both of which are upregulated in response to mibefradil treatment, abrogated drug-induced cell death, suggesting a role for p27 and BAX in mediating mibefradil toxicity. Also, overexpression of mTOR, which is downregulated in response to mibefradil treatment, inhibited drug-induced cell death.
To understand the effect of mibefradil on the transcriptome, we performed RNA-seq. We found that mibefradil treatment resulted in a decrease in expression of several oncogenes such as PDGFA, PDGFB, TGFB1, METTL7B, EGR3 and TNFRSF12A, and an increase in the expression of numerous tumor suppressors including TNFRSF14 and HSD17B14, confirmed by qRT-PCR. These data provide insights into the molecular basis of responsiveness to Cav3.2 inhibition in cancer cells suggesting an important role for mibefradil in the regulation of genes implicated in cancer. In addition to the changes in protein function and gene transcription described above, blocking Cav3.2 might also influence GSC function by affecting resting membrane potential. In fact, recently published research has shown that brain tumor stem cells have elevated resting membrane potential that is regulated by connexins and EAG2 potassium channels to influence these cells' malignant functions (49, 50) . enrolling recurrent GBM patients to study the effect and safety of mibefradil combined with hypofractionated radiation therapy. This emphasizes the relevance of our study in establishing the molecular and functional basis of Cav3.2 targeting for GBM therapy. Our data also suggest that mibefradil is likely to achieve greater clinical benefits in patients in combination with TMZ.
Altogether, our data show novel roles and mechanisms of action of T type calcium channel Cav3.2 in GSCs and GBM ( Supplementary Fig. 4 ) and support the use of mibefradil in combination with TMZ for GBM therapy. 
